Table 1: Molecular Subtypes of Breast Cancer
Table 2: AJCC Stage Definitions for Breast Cancer
Table 3: Prognosis for Breast Cancer
Table 4: Risk Factors and Comorbidities for Breast Cancer
Table 5: 8MM, Most Recent Five-Year Relative Survival for Invasive Breast Cancer, Women (%)
Table 6: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incidence of Non-Invasive DCIS Breast Cancer
Table 7: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status
Table 8: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incidence of Invasive Breast Cancer
Table 9: 8MM, Sources of Epidemiological Data Used to Forecast Invasive Breast Cancer by HER2 Status
Table 10: 8MM, Sources of Epidemiological Data Used to Forecast the Relative Survival of Invasive Breast Cancer
Table 11: 8MM, Sources of Epidemiological Data Used to Forecast HER2+ Invasive Breast Cancer by Stage at Diagnosis
Table 12: 8MM, Sources of Epidemiological Data Used to Forecast HER2-, HR+ Invasive Breast Cancer by Stage at Diagnosis
Table 13: 8MM, Sources of Epidemiological Data Used to Forecast TN Invasive Breast Cancer by Stage at Diagnosis
Table 14: 8MM, Sources of Epidemiological Data Used to Forecast HER2-Specific Invasive Breast Cancer by Menopausal Status
Table 15: 8MM, Sources of Epidemiological Data Used to Forecast HER2+ Invasive Breast Cancer by Site of Metastasis
Table 16: 8MM, Sources of Epidemiological Data Used to Forecast HER2-Specific Invasive Breast Cancer by Type of Biomarker Expression
Table 17: 8MM, Sources Not Used in Epidemiological Analysis of Breast Cancer
Table 18: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer, Women, Ages =18 Years, N, Select Years, 2015–2025
Table 19: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status, Women, Ages =18 Years, N, 2015
Table 20: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages =18 Years, N, Select Years, 2015–2025
Table 21: 8MM, Age-Specific Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages =18 Years, N (Row %), 2015
Table 22: 8MM, Five-Year Diagnosed Prevalent Cases of Invasive Breast Cancer, Women, Ages =18 Years, N, Select Years, 2015–2025
Table 23: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer by Stage at Diagnosis, Women, Ages =18 Years, N, 2015
Table 24: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer by HER2 Status, Women, Ages =18 Years, N, 2015
Table 25: Treatment Guidelines for HER2- Breast Cancer
Table 26: Most Prescribed Regimens for HER2- Breast Cancer by Drug Class in the Global Markets, 2015
Table 27: Country Profile – US
Table 28: Country Profile – France
Table 29: Country Profile – Germany
Table 30: Country Profile – Italy
Table 31: Country Profile – Spain
Table 32: Country Profile – UK
Table 33: Country Profile – Japan
Table 34: Country Profile – China
Table 35: Product Profile – Ibrance
Table 36: Summary of the Results of the PALOMA-2 Trial
Table 37: Summary of the Results of the PALOMA-3 Trial
Table 38: Safety profile of Ibrance + letrozole
Table 39: Safety Profile of Ibrance in Combination with Faslodex
Table 40: Ibrance SWOT Analysis, 2016
Table 41: Product Profile – Abraxane
Table 42: Efficacy of Abraxane
Table 43: Safety Profile of Abraxane
Table 44: Abraxane SWOT Analysis, 2016
Table 45: Product Profile – Afinitor (everolimus)
Table 46: Efficacy of Afinitor in Second-Line HER2-/HR+ Advanced Breast Cancer
Table 47: Safety Profile of Afinitor
Table 48: Afinitor SWOT Analysis, 2016
Table 49: Product Profile – Avastin
Table 50: Efficacy of Avastin in First Line Metastatic Breast Cancer
Table 51: Safety of Avastin in First-Line Metastatic Breast Cancer
Table 52: Avastin SWOT Analysis, 2016
Table 53: Product Profile – Halaven
Table 54: Efficacy of Halaven
Table 55: Safety Profile of Halaven
Table 56: Halaven SWOT Analysis, 2016
Table 57: Product Profile – Ixempra
Table 58: Efficacy of Ixempra Monotherapy
Table 59: Efficacy of Ixempra in Combination with Xeloda
Table 60: Safety Profile of Ixempra
Table 61: Ixempra SWOT Analysis, 2016
Table 62: Product Profile – Faslodex
Table 63: Efficacy of Faslodex in the First Line
Table 64: Efficacy of Faslodex Monotherapy in the Second Line
Table 65: Efficacy of Faslodex in the First Line
Table 66: Safety of Faslodex in the First Line
Table 67: Safety of Faslodex in the Second Line
Table 68: Faslodex SWOT Analysis, 2016
Table 69: Product Profile – Doxil
Table 70: Doxil SWOT Analysis, 2016
Table 71: Product Profile – Nolvadex/Soltamox
Table 72: AI Approvals in the 8MM
Table 73: Unmet Need and Opportunity in HER2- Breast Cancer
Table 74: Product Profile – Abemaciclib (LY2835219)
Table 75: Efficacy of Abemaciclib in Monotherapy in Pretreated HER2-/HR+ Metastatic Breast Cancer Patients (MONARCH 1 NCT02102490)
Table 76: Safety of Abemaciclib in Monotherapy in Pretreated HER2-/HR+ Metastatic Breast Cancer Patients
Table 77: Abemaciclib SWOT Analysis, 2016
Table 78: Product Profile – Ribociclib
Table 79: Efficacy of Ribociclib in Combination with Letrozole in HER2-/HR+ Metastatic Breast Cancer Patients (MONALEESA 2, NCT01958021)
Table 80: Most Common AEs of Ribociclib in Combination with Letrozole in HER2-/HR+ Metastatic Breast Cancer Patients (MONALEESA 2, NCT01958021)
Table 81: Ribociclib SWOT Analysis, 2015
Table 82: Product Profile – Lynparza
Table 83: Summary of the Results of the ICEBERG 1 Phase II Trial (NCT00494234)
Table 84: Summary of the Most Commonly Reported AEs, Occurring in at Least 20% of Patients With Advanced Ovarian Cancers Treated with Lynparza Monotherapy
Table 85: Lynparza SWOT Analysis, 2016
Table 86: Product Profile – Talazoparib
Table 87: Summary of the Most Commonly Reported AEs in Patients Treated with Talazoparib Monotherapy
Table 88: Talazoparib SWOT Analysis, 2016
Table 89: Product Profile – Veliparib
Table 90: Veliparib SWOT Analysis, 2016
Table 91: Product Profile – Niraparib
Table 92: Summary of the Main Reported AEs in Ovarian Cancer Patients Treated with Niraparib
Table 93: Niraparib SWOT Analysis 2016
Table 94: Product Profile – Buparlisib (BKM-120)
Table 95: Summary of the Results of the Trial of Buparlisib + Faslodex vs. Faslodex
Table 96: Summary of AEs From the Trial of Buparlisib + Faslodex vs. Faslodex
Table 97: Buparlisib SWOT Analysis
Table 98: Product Profile – Alpelisib (BYL- 719)
Table 99: Summary of the Results of the Alpelisib Trial
Table 100: Summary of AEs from the Trial of Alpelisib
Table 101: Alpelisib SWOT Analysis
Table 102: Product Profile – Taselisib (GDC-0032)
Table 103: Summary of the Results of the Taselisib Trial
Table 104: Summary of the Safety of Taselisib
Table 105: Taselisib SWOT Analysis
Table 106: Product Profile – Tecentriq
Table 107: Summary of the Results of the Phase Ib Trial of Tecentriq in Combination with Abraxane in Patients with mTNBC (Genetech, NCT01633970)
Table 108: Summary of AEs from the Phase Ib Trial of Tecentriq + Abraxane in Patients with mTNBC (Genetech, NCT01633970)
Table 109: Tecentriq SWOT Analysis, 2016
Table 110: Product Profile – Keytruda (Pembrolizumab)
Table 111: Summary of the Results of Keytruda in HER2-/HR+ Patients in the KEYNOTE-028 Trial (MSD, NCT02054806)
Table 112: Summary of AEs of All Grades for Keytruda in HER2-/HR+ Patients in the Keytruda KEYNOTE-028 Trial (MSD, NCT02054806)
Table 113: Summary of Grade 3-4 AEs from the Trial of Keytruda (MSD, NCT02054806)
Table 114: Keytruda SWOT Analysis, 2016
Table 115: Product Profile – Entinostat
Table 116: Efficacy Results from the ENCORE301 Trial of Exemestane + Entinostat vs. Exemestane + Placebo
Table 117: Most Commonly Reported AEs from the ENCORE301 trial of Exemestane + Entinostat vs. Exemestane + Placebo
Table 118: Entinostat SWOT, 2016
Table 119: Product Profile – Epidaza
Table 120: Most Commonly Reported AEs from the Phase II Trial of Epidaza + Exemestane
Table 121: Epidaza SWOT Analysis
Table 122: Product Profile – Sacituzumab Govitecan
Table 123: Summary of the Results of Sacituzimab Govitecan Phase I/II Trial in Metastatic TNBC (Immunomedics Inc., NCT01631552)
Table 124: Summary of AEs from the Phase I/II Trial of Sacituzimab Govitecan (Immunomedics Inc., NCT01631552)
Table 125: Sacituzimab Govitecan SWOT, 2016
Table 126: Product Profile – Glembatumumab vedotin
Table 127: Efficacy Results of the Phase IIb EMERGE Trial of Glembatumumab Vedotin Monotherapy in Metastatic TNBC (NCT01156753)
Table 128: Safety Results of the Phase IIb EMERGE Trial of Glembatumumab Vedotin Monotherapy in Solid Tumors
Table 129: Glembatumumab Vedotin SWOT, 2016
Table 130: Product Profile – Xtandi
Table 131: Summary of the Results of ENZA Phase II Xtandi Trial (NCT01889238)
Table 132: Summary of the Results of Xtandi Trial
Table 133: Xtandi SWOT Analysis, 2016
Table 134: Early Stage Clinical Development in HER2- Breast Cancer
Table 135: Key Companies in the Disease HER2- Breast Cancer Market in the 8MM, 2015
Table 136: Pfizer’s HER2- Metastatic Breast Cancer Portfolio Assessment, 2016
Table 137: Novartis’ HER2- Metastatic Breast Cancer Portfolio Assessment, 2016
Table 138: Roche’s HER2- Breast Cancer Portfolio Assessment, 2016
Table 139: AZ’s HER2- Breast Cancer Portfolio Assessment, 2016
Table 140: Global HER2- Breast Cancer Market – Drivers and Barriers, 2015–2025
Table 141: Key Events Impacting Sales for HER2-/HR+ in the US, 2015–2025
Table 142: Key Events Impacting Sales for TNBC in the US, 2015–2025
Table 143: US HER2- Breast Cancer Market – Drivers and Barriers, 2015–2025
Table 144: Key Events Impacting Sales for HER2-/HR+ Breast Cancer in the 5EU, 2015–2025
Table 145: Key Events Impacting Sales for TNBC in the 5EU, 2015–2025
Table 146: 5EU HER2- Breast Cancer Market – Drivers and Barriers, 2015–2025
Table 147: Key Events Impacting Sales for HER2-/HR+ breast cancer in Japan, 2015–2025
Table 148: Key Events Impacting Sales for TNBC in Japan, 2015–2025
Table 149: Japanese HER2- Breast Cancer Market – Drivers and Barriers, 2015–2025
Table 150: Key Events Impacting Sales for HER2-/HR+ Breast Cancer in China, 2015–2025
Table 151: Key Events Impacting Sales for TNBC in China, 2015–2025
Table 152: Chinese HER2- Breast Cancer Market – Drivers and Barriers, 2015–2025
Table 153: Key Launch Dates in HER2- Breast Cancer
Table 154: Key Patent Expiries
Table 155: Average Body Weight and Surface Area Across the 8MM
Table 156: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country